336 related articles for article (PubMed ID: 28241093)
1. Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma.
Miwa S; Nishida H; Tanzawa Y; Takeuchi A; Hayashi K; Yamamoto N; Mizukoshi E; Nakamoto Y; Kaneko S; Tsuchiya H
Cancer; 2017 May; 123(9):1576-1584. PubMed ID: 28241093
[TBL] [Abstract][Full Text] [Related]
2. TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.
Miwa S; Nishida H; Tanzawa Y; Takata M; Takeuchi A; Yamamoto N; Shirai T; Hayashi K; Kimura H; Igarashi K; Mizukoshi E; Nakamoto Y; Kaneko S; Tsuchiya H
PLoS One; 2012; 7(12):e52926. PubMed ID: 23300824
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors.
Suminoe A; Matsuzaki A; Hattori H; Koga Y; Hara T
Pediatr Transplant; 2009 Sep; 13(6):746-53. PubMed ID: 19067917
[TBL] [Abstract][Full Text] [Related]
4. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma.
Matsuzaki A; Suminoe A; Hattori H; Hoshina T; Hara T
J Pediatr Hematol Oncol; 2002; 24(3):220-3. PubMed ID: 11990310
[TBL] [Abstract][Full Text] [Related]
8. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
9. Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines.
Goldberg JM; Fisher DE; Demetri GD; Neuberg D; Allsop SA; Fonseca C; Nakazaki Y; Nemer D; Raut CP; George S; Morgan JA; Wagner AJ; Freeman GJ; Ritz J; Lezcano C; Mihm M; Canning C; Hodi FS; Dranoff G
Clin Cancer Res; 2015 Jul; 21(14):3178-86. PubMed ID: 25805798
[TBL] [Abstract][Full Text] [Related]
10. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
Yonemoto T; Tatezaki S; Ishii T; Satoh T
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1431-5. PubMed ID: 10500530
[TBL] [Abstract][Full Text] [Related]
11. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
Alfaro C; Perez-Gracia JL; Suarez N; Rodriguez J; Fernandez de Sanmamed M; Sangro B; Martin-Algarra S; Calvo A; Redrado M; Agliano A; Gonzalez A; Rodriguez I; Bolaños E; Hervás-Stubbs S; Perez-Calvo J; Benito A; Peñuelas I; Vigil C; Richter J; Martinez-Forero I; Melero I
J Immunol; 2011 Dec; 187(11):6130-42. PubMed ID: 22048768
[TBL] [Abstract][Full Text] [Related]
12. [Bone and soft-tissue tumors].
Shirai Y; Nakase T
Gan To Kagaku Ryoho; 1986 Jan; 13(1):30-6. PubMed ID: 3002285
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
Geiger JD; Hutchinson RJ; Hohenkirk LF; McKenna EA; Yanik GA; Levine JE; Chang AE; Braun TM; Mulé JJ
Cancer Res; 2001 Dec; 61(23):8513-9. PubMed ID: 11731436
[TBL] [Abstract][Full Text] [Related]
14. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
Zhu X; Lu C; Xiao B; Qiao J; Sun Y
J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of relapsed or refractory non-Hodgkin's lymphoma by antigen specific dendritic cells-activated lymphocytes].
Sun Y; Chen J; Cai P; Hu YH; Zhong GC; Feng HZ; Min M; Li S; Zhang C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):219-23. PubMed ID: 20137151
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.
Vilella R; Benítez D; Milà J; Lozano M; Vilana R; Pomes J; Tomas X; Costa J; Vilalta A; Malvehy J; Puig S; Mellado B; Martí R; Castel T
Cancer Immunol Immunother; 2004 Jul; 53(7):651-8. PubMed ID: 14999431
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.
Iwashita Y; Tahara K; Goto S; Sasaki A; Kai S; Seike M; Chen CL; Kawano K; Kitano S
Cancer Immunol Immunother; 2003 Mar; 52(3):155-61. PubMed ID: 12649744
[TBL] [Abstract][Full Text] [Related]
18. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.
Mahvi DM; Shi FS; Yang NS; Weber S; Hank J; Albertini M; Schiller J; Schalch H; Larson M; Pharo L; Gan J; Heisey D; Warner T; Sondel PM
Hum Gene Ther; 2002 Sep; 13(14):1711-21. PubMed ID: 12396624
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
